Trial Information

Summary: Alzheimer's study

Alzheimer's Disease is a neurodegenerative disorder in which brain cells are lost. It is characterized by progressive loss of memory and cognitive function, such as movement control and decision making ability. It is the most common cause of dememtia in the elderly and affects about 18 million people worldwide - 5 million in the U.S. alone. Although there is no cure for Alzheimer's Disease, research is under way to find a new investigational treatment aimed at slowing down the progression of the disease.

Who is eligible for the ICARA study:
You may be eligible if you:

• Are between 50 and 88 years of age
• Have a diagnosis of probable Alzheimer's disease
• Have a caregiver that is willing to be involved in the study with you

Participants will receive, at no charge, the investigational drug, physical exams and the laboratory services and tests.

What will participants be asked to do?

• Attend 15 study visits during the 83 week period
• Receive six infusions of the investigational drug every 13 weeks for 65 weeks
• Have blood tests and study-related physical and clinical exams

If you would like to learn more about participating in this study, please send an e-mail message using the form below.